Get started
AbbVie Inc.AbbVie Inc.AbbVie Inc.

AbbVie Inc.

No trades
No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsOptionsBondsETFs

In-depth trading ideas


Discover detailed market analysis from traders. See how others approach this instrument, compare different strategies, and discover perspectives that can shape your own view.
Trade ideasMinds
$ABBV — WEDGE BREAK ON A VOLUME EXPLOSION 📊 NYSE:ABBV — WEDGE BREAK ON A VOLUME EXPLOSION | 1W Weekly close $253.35, +𝟭𝟳% on the week. This is a structural break, not a drift. 💥 THE VOLUME TELL 𝟴𝟳.𝟱𝗠 shares — the largest volume bar on the entire chart, by a wide margin. A breakout this size on volume this heavy is the confirmation you want. Wedge breaks that fail usually fail on weak volume. This one didn't. 🔓 THE BREAK Price broke clean out of the descending consolidation wedge (converging trendlines off the Oct-2025 $239 high). The candle cleared: ▪ the wedge upper rail ▪ the CHoCH ▪ the Weak High (~$253) ▪ into PREMIUM (above the 1.236 fib / $258 zone) 🪞 Structure flipped. Equilibrium reclaimed, premium entered, momentum confirming. 📐 THE MEASURED MOVE Wedge height ≈ $50 (range low ~$188 → high ~$239). Projected from the ~$253 breakout → ~$𝟯𝟬𝟯. The kicker: that lines up almost exactly with the 𝟭.𝟳𝟴𝟲 fib ($303.11) AND your $302.98 horizontal. Measured move + fib extension agree = the target isn't arbitrary. That's the confluence that matters. 📈 THE PATH ▪ Next resistance: 1.236 $258 → 1.382 $270 → 1.5 $280 → 1.618 $289 → 𝗧𝗔𝗥𝗚𝗘𝗧 1.786 $303 ▪ RSI 67, rising, crossed its signal — momentum behind it, NOT yet overbought (sub-70 leaves room) 🪞 Clean ladder of fib resistance into $303. Each level is a checkpoint, not a wall — but watch $258 (premium entry) for the first pause. 🛡 INVALIDATION A weekly close back INSIDE the wedge / below the breakout (~$240, the prior range high) negates it. That's the line — below it, the break failed and it's a fakeout retest. 🪞 THE READ This is a textbook setup: multi-month wedge, explosive volume break, measured move and fib extension agreeing on ~$303, RSI confirming with room left. The volume is what separates this from a fade — 87M doesn't show up on noise. I want to see it HOLD above the breakout (~$240) on any pullback; a retest that holds is the highest-quality entry. Don't chase the +17% candle extended — let it confirm the breakout as support, then ride the ladder to $303. ⚔ Volume confirmed the break. Measured move = $303. Let it
NYSE:ABBVLong
by CEO_of_WaverVanir_Int_LLC
2
Just got tapped in ABBV, Funny Don't know what this company does Note: Don't know what this symbol or company does nor do I care, As technical analyst that's not my job, I have been keeping an eye on this & have been waiting as usual only few things is going to happen: 1. SL hit. 2. BE hit. 3. Hopefully Profit booking. 4. But also on Monday either a gap up OR gap down (Doesn't matter about gap down as I have risked only 0.5% on this trade) It's not like I've liquidated my wealth trading this... Let's which one thing is going to happen.
NYSE:ABBVLong
by happyrajofficial
AbbVie (ABBV) Breaking Above a Major Resistance Zone AbbVie has decisively broken above the long-standing resistance around $245, turning a key supply zone into potential support. The strong bullish breakout suggests renewed buying momentum, although a short-term pullback to retest the breakout level remains possible before the next leg higher. Short-Term Outlook As long as price remains above $245, the bullish breakout remains valid. Targets: $260 → $270 → $280 Stop-loss: Below $242 Long-Term Outlook The long-term trend continues to favor the bulls, with the breakout confirming a continuation of the broader uptrend. If the former resistance successfully turns into support, it could become the base for another sustained rally. Targets: $280 → $300 → $320 Stop-loss: Weekly close below $235 Summary AbbVie has successfully broken above the major $245 resistance level, which is now expected to act as support. If buyers continue defending this breakout zone, the stock could extend its rally toward $270+, with the potential to reach the $300–320 area over the longer term. However, a failure to hold above $245 would weaken the breakout and increase the risk of a deeper pullback toward the $230–235 support zone.
NYSE:ABBVLong
by isahebdadi
AbbVie at a Breakout Decision PointAbbVie is trading near the upper boundary of a descending channel, making this a critical area where the stock must either break out or remain trapped in the corrective structure. Short-Term Outlook A daily close above $230 would strengthen the bullish breakout scenario. Targets: $235 → $245 → $250 Stop-loss: Below $220 Long-Term Outlook The broader uptrend remains intact despite the ongoing correction. A confirmed breakout from the channel could signal the start of a new bullish leg. Targets: $250 → $260 → $275 Stop-loss: Weekly close below $210 Summary AbbVie is testing the top of a descending channel after months of consolidation. A successful breakout above $230 could open the door to $245–250 in the short term and potentially $260+ over the longer term. However, rejection from current levels may send the stock back toward the channel midpoint around $210–215 before buyers regain control.
NYSE:ABBVShort
by isahebdadi
ABBV short idea ABBV looks to have formed a triple top / channel resistance and has since broken down into a tightening symmetrical triangle. Price is currently holding the 50% fib support at ~$204, with the .618 below at ~$195. We’ve seen multiple tests of the $204 support, and each bounce is getting weaker while bulls continue to fail reclaiming the $206–207 area. This suggests buyer exhaustion and increases the likelihood of a breakdown. I’m looking for a move lower out of the triangle. A break below $204 and flip to resistance could lead to a move toward $201, then $195, with a potential extension to $180. Invalidation: A strong move and hold above $208 would shift the structure bullish and invalidate the short idea.
NYSE:ABBVShort
by Erictaylor
NYSE – S&P 500 | AbbVie Inc. | 23 Mar 2026Part of the ongoing S&P 500 Structural Census study. AbbVie reflects a sustained impulsive structure following the post-2020 expansion phase, with price maintaining higher highs and higher lows. The current phase represents consolidation within the broader uptrend, with no confirmed structural weakness. Structural Status: Sustained Impulsive Structure This analysis is for educational purposes and reflects structural market observation. Structure → Level → Trigger → Probability #SP500Census #MarketStructure #StructuralAnalysis #ABBV #EwavesJournal
NYSE:ABBV
by kacraj
AbbVie Under PressureTechnical Analysis The daily chart shows a descending channel, indicating a correction after a strong rally. Key points: • Strong prior uptrend • Current corrective channel • Price near channel support • Moving average acting as resistance Short-Term Scenarios Bullish Bounce If price holds $200–205 and reclaims $215: Targets: $215 $225 $235 Stop loss $198 Bearish Breakdown If support breaks: Targets: $195 $185 $180 Stop loss $210 Long-Term Outlook AbbVie Inc. still maintains a relatively bullish structure. Targets: $240 $260 $280 Stop loss Below $180 Fundamental Overview AbbVie is a major pharmaceutical company. Pros: • Stable revenue • Strong dividend • Solid pipeline Cons: • Drug dependency risks • Regulatory pressure Final Insight Above $215 → bullish recovery Below $200 → deeper correction
NYSE:ABBVLong
by isahebdadi
waitTeam, We are not buying now. Price is still trading below major descending resistance (R). As long as we are below R, the structure remains under pressure. ✅ What We Are Waiting For We only buy if: Price breaks above the descending resistance (R) A candle closes clearly above it We see strength (no immediate rejection wick) Ideally: a small pullback that holds above R No breakout = no trade. 🟢 Entry Plan (After Confirmation) Once price: Breaks above R Retests and holds
NYSE:ABBVLong
by SIMMONSCAPITAL
ABBV Moderate Bull Holding Strong Breakout ZoneNYSE:ABBV 28/02/2026 💰 231.02 🟢 Moderate BULL 16.23% at 1.39x 🟢(58.1%):🔴(41.9%) ⏳Clarity:54% Retrace:-0.5% Bounce:3.2% 5.9x 💥 BO+ Bulls are holding the edge here but this is not an aggressive setup. The multi-timeframe count shows 36 green against 24 red across 112 signals, with the higher timeframe trend leaning bullish at 9 green versus 5 red. EMA structure is clean with 13 green and zero red, meaning the trend backbone is intact across all measured timeframes. Ichi TK adds further confirmation at 10 green to 4 red. Where it gets interesting is the breakout classification. The 5.9x reading with BO+ status tells us this move has legs beyond a simple bounce. Price is sitting at the 90th percentile near the upper range between 221.26 and 232.10. Retrace is minimal at just -0.5% which shows buyers are not giving back ground. The cautious part of this read comes from candles. The candlestick count is weak at 3 green versus 11 red, and pattern totals lean bearish at 1 green to 2 red with 2 bearish harami and 2 engulfing reds showing up. This means short-term price action is choppy even though the structural trend is bullish. Spread sits at 20% moderate so there is no extreme extension either way. Volume tells a mixed story. Vol Z is at -0.61 which is quiet, and momentum is decelerating at -1.35. The Bull Bear Z readings are both negative at -0.37 and -0.45 showing neither side is pushing hard on volume. No whale activity detected and no volume squeeze forming. However OBV Z at 2.43 with a strong upward trend is the standout signal here. Accumulation is happening under the surface even though daily volume is not flashy. S.Mom shows expansion declining at 900.6% which means the big move energy is fading but still elevated. No futures data available for this ticker so there is no leverage or derivatives distortion to worry about. This is a clean spot market read. The setup favors longs but patience is key. Clarity at 54% is moderate and the candle weakness suggests pullbacks are possible before continuation. Best approach is to watch for a retrace toward the 221 to 225 zone for a better entry rather than chasing up here near 232 resistance. If OBV continues to climb while price consolidates that would be the ideal reload zone. More analysis on my profile. 🎯 Target: 1K Followers 👉 Follow: stingrayea
NYSE:ABBVLong
by stingrayea
ABBVIE A -25% correction is the norm at this point.AbbVie Inc. (ABBV) has topped on its historic 13-year Channel Up and since its October 2025 All Time High (ATH), which was a Higher High for the pattern, it has been trading sideways at best. This is a strong indication of a potential long-term correction, the likes of which we've been seeing cyclically since its IPO. Since 2022 we've had two -25% corrections on average, both hitting the 1W MA50 (red trend-line) before bottoming and reversing. Before that we've had ABBV's strongest ever correction in 2018-2019 and in 2015 a -36.50% one, both of which touched at lest the 1M MA50 (blue trend-line). As a result, if we see another -24.65% correction in 2026 from the ATH, expect the price to the 195.00 - 185.00 Target Zone. The first will make contact with the 1W MA150 and the last with the 1M MA50. The 1M RSI Support Zone is an additional buy indicator if hit. --- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** --- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVShort
by TradingShot
abbv building strengthas we can see abbv is in a bullish channel. we are starting to form a bull flag inside this channel. if we don't break down from this channel, we have a possible target at the top of the channel @275 simple annalist with support and resistant shows us. we have support at 215 if price hits target and doesn't break out of the channel we will have a great buying opportunity with a confluence of support. we have been consolidating sideways for 150 days. we can be in an accumulation zone waiting for a breakout. also, obv indicator is rising during this sideway price range that often confirms accumulation.
NYSE:ABBVLong
by Mrbigman
AbbVie in Descending ChannelAfter a strong impulsive rally (black trendline leg), price entered a descending parallel channel, indicating a corrective phase rather than a confirmed trend reversal — at least for now. Current price: ~231 Price is testing the upper boundary of the descending channel. 🔎 Structure Overview • Prior structure: Strong bullish impulse • Current structure: Bearish correction (lower highs + lower lows inside channel) • Moving average flattening → momentum cooling • Price sitting at resistance (channel top) This is a breakout vs continuation decision zone. 🟢 Bullish Scenario (Channel Breakout) If: • Daily close above 235–238 • Strong follow-through candle • Volume expansion Upside targets: • 245 • 255 • Potential continuation toward 265 This would invalidate the corrective channel and signal trend continuation. Long Invalidation: • Rejection from channel top + close below 225 🔴 Bearish Scenario (Correction Continues) If: • Price rejects current resistance • Break below 220 Downside targets: • 210 • 200 (channel base) • Possible overshoot toward 195 This would confirm continuation of corrective structure. Short Invalidation: • Break and hold above 238 📊 Structural Insight Important distinction: • This looks more like a bullish trend in correction, not a full trend reversal yet. • Breakout from descending channel often triggers strong upside expansion. • Failure at resistance increases probability of retest of channel lows.
NYSE:ABBVShort
by isahebdadi
AbbVie in Descending ChannelThe chart shows AbbVie Inc. (ABBV) on the daily timeframe. After a strong impulsive rally (black trendline leg), price entered a descending parallel channel, indicating a corrective phase rather than a confirmed trend reversal — at least for now. Current price: ~231 Price is testing the upper boundary of the descending channel. 🔎 Structure Overview • Prior structure: Strong bullish impulse • Current structure: Bearish correction (lower highs + lower lows inside channel) • Moving average flattening → momentum cooling • Price sitting at resistance (channel top) This is a breakout vs continuation decision zone. 🟢 Bullish Scenario (Channel Breakout) If: • Daily close above 235–238 • Strong follow-through candle • Volume expansion Upside targets: • 245 • 255 • Potential continuation toward 265 This would invalidate the corrective channel and signal trend continuation. Long Invalidation: • Rejection from channel top + close below 225 🔴 Bearish Scenario (Correction Continues) If: • Price rejects current resistance • Break below 220 Downside targets: • 210 • 200 (channel base) • Possible overshoot toward 195 This would confirm continuation of corrective structure. Short Invalidation: • Break and hold above 238 📊 Structural Insight Important distinction: • This looks more like a bullish trend in correction, not a full trend reversal yet. • Breakout from descending channel often triggers strong upside expansion. • Failure at resistance increases probability of retest of channel lows.
NYSE:ABBVLong
by isahebdadi
ABBV Will Fly Once This HappensABBV Will Fly Once This Happens NYSE:ABBV is one of those incredible companies, not just because of what they do, but how they do it. They have consistently ranked among the best for employee well-being while successfully bringing to market some of the most patent-protected biotech drugs, such as Humira . Furthermore, they continue to develop even more advanced treatments that are expected to surpass previous sales records. Since 2013, the company has seen steady growth , and there are no signs of that slowing down. While these types of stocks are fantastic, they rarely offer clear entry points that allow you to avoid significant drawdowns. Today, we have an opportunity to enter at the breakout of a bull flag (or channel). This is a clear bullish continuation pattern that aligns perfectly with analyst price targets and the positive progress of their current research and drug pipeline. Breaking above the channel, specifically the $235 mark, would be a strong signal to enter. Given the expected upward momentum, we could use a very tight Stop Loss (SL). I have marked the Fibonacci levels, but this is the kind of stock you could simply hold in a portfolio long-term after a perfect entry. That said, my philosophy is to capture the profit during the rally and then move on to the next opportunity, so I will be focusing on those Fibonacci levels for my exit. On the downside, I would be concerned if we lost $210 , as that could lead us straight to $190 . At that level, I expect to see plenty of buyers, making it an excellent entry point. If that level fails to hold, the bullish trend would likely be over, and it would be best to stay out. Currently, however, it looks like the price is preparing for an imminent upward move. How far ABBV can go? Short-to-Medium Term : If the $235 breakout holds, the immediate Fibonacci extensions often point toward the $255 - $265 range. Long-Term : As long as their new immunology assets (like Skyrizi and Rinvoq) continue to fill the Humira gap, ABBV is positioned as a powerhouse. In a sustained bullish market, seeing it test the $280 - $300 psychological levels over the next 18–24 months is well within the realm of analyst projections. What would be your exit strategy if the price breaks the bull flag? Do you consider a long term hold here? Or a fast profit? 👇 WANT MORE? 🚀 Hit the rocket, read my profile and follow so we can find each other again.
NYSE:ABBVLong
by TopChartPatterns
1
AbbVie Inside a Falling ChannelAbbVie is currently trading inside a descending channel, following a strong impulsive bullish move. This structure suggests a controlled correction rather than a trend reversal, at least for now. Price is oscillating around the midline of the channel and near the moving average, indicating short-term balance between buyers and sellers. As long as price remains within the channel, ABBV is technically in a corrective phase. Bullish Scenario • Holding above $205–210 (lower boundary of the channel) • A bounce toward the channel midline or upper boundary • Upside targets: • $225 • $235 • A breakout above the channel would confirm trend continuation. Bearish Scenario • Daily close below $205 • Bearish continuation toward: • $195 • $185 🛑 Stop Loss (English) • Long positions: below $203 • Short positions: above $228 after rejection from resistance
NYSE:ABBVLong
by isahebdadi
AbbVie tests $225 as buyers step in ahead of catalysts:Current Price: 223.01 (Analysis was generated on Monday Morning) Direction: LONG Confidence level: 58%(Limited volume of trader commentary but consistent focus on $219 support and price holding above key moving averages supports a cautious long bias.) Targets Target 1: 225.00 Target 2: 226.00 Stop Levels Stop 1: 221.00 Stop 2: 219.00 Key Insights: Here’s what’s driving this setup. Price is trading above both the 20‑day and 50‑day moving averages, and several traders point out that this structure usually favors upside continuation as long as $219 holds. Volume has expanded compared with the recent average, which tells me buyers aren’t passive here—they’re committing capital. What’s interesting is the tone from traders discussing near‑term action. While conviction isn’t aggressive, many are framing AbbVie as a “buy on dips” name going into earnings and FDA‑related headlines. When price is sitting closer to support than resistance and holding trend, I lean toward the upside, even with modest confidence. Recent Performance: AbbVie pushed up to the $223 area after a solid earnings reaction and has held those gains rather than fading them. Over the last sessions, dips toward $221 have attracted buyers quickly, suggesting institutions are defending that zone. That behavior matters more to me than raw sentiment counts. Expert Analysis: Several professional traders I’m tracking highlighted $219 as the line in the sand. As long as price stays above it, they expect attempts at $225 and potentially a quick extension to $226. RSI in the high‑50s supports this view—it shows momentum without flashing exhaustion. No one is calling for a breakout run this week, but a grind higher fits the current tape. News Impact: Recent headlines around earnings strength, raised guidance, and continued investment in manufacturing add a supportive backdrop. The upcoming earnings and FDA discussions are real catalysts, and traders tend to position ahead of those rather than after them. That anticipation is likely helping keep a bid under the stock. Trading Recommendation: Putting it all together, I’m favoring a LONG position while AbbVie holds above $221. I’d look for a move into $225 first and then $226 if momentum stays intact. Risk is clearly defined—if $219 breaks, the trade thesis is invalid and I’m out. This isn’t a high‑conviction swing, but it’s a clean, well‑defined setup for the week with manageable downside.
NYSE:ABBVLong
by CrowdWisdomTrading
ABBV Stock Analysis [1D TF] Fundamental/Market Context AbbVie (ABBV) continues to benefit from a diversified portfolio led by strong immunology and oncology franchises. Recent earnings have generally topped expectations, supporting confidence in cash flow and dividend sustainability, while pipeline catalysts provide medium-term support. Technical Analysis Technically, ABBV remains bullish with the 50EMA above the 200EMA, indicating structural strength. After a pullback, price has successfully reclaimed the 50EMA and is showing upward momentum. The RSI is trending higher, reinforcing positive momentum and suggesting buyers are returning. Strategy The setup favours entering long on a confirmed bullish signal above the 50EMA, ideally through a strong reversal candle or decisive close. Staying aligned with the prevailing uptrend increases the probability of continuation toward recent highs. Risk Risks include any failure to hold above the 50EMA, which could weaken the short-term trend, and fundamental headwinds such as pricing pressure or competitive entrants in key therapeutic areas. Broader market volatility could also impact healthcare valuations, so defined stops and disciplined sizing remain essential.
NYSE:ABBVLong
by SmiertSpionam
1
ABBVIE topped and looks for a 2026 Bear Cycle.AbbVie Inc. (ABBV) has been trading within a Channel Up for almost the past 4 years (since the April 04 2022 High) and seems to have topped on its latest September 29 2025 Higher High as it turned sideways since. On that September top, the 1W RSI also got rejected from overbought territory, which is where a number of Higher High peaks within this pattern started Bearish Leg corrections. As you can see all of those Bearish Legs tested at least the 1W MA100 (green trend-line) before reversing into Bullish Legs, with the minimum decline bein -16.11% and the maximum -24.88%. If we exclude that -16.11%, all other corrections had the 1W RSI test the 4-year Support Zone. As a result, we establish a Target Zone of $195.00 - $185.00 as a potential bottom zone of the current Bear Cycle. Interestingly, the top of this zone is where the stock would make contact with the 1W MA100, while the bottom would test the 1W MA200 (orange trend-line), which is the market's long-term Support. If the 1W RSI hits its Support Zone and then rebounds earlier, that would be a level to enter a long-term buy regardless of the price. --- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** --- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVShort
by TradingShot
Healthy Pullback or Trend Reversal?Bullish Scenario (Primary) • Strong uptrend structure • Sharp impulse move followed by bullish consolidation (triangle) • Pullback is constructive, not trend-breaking • Price holding above 50-day SMA 📍 Entry Zone: • $225 – $230 🛑 Stop Loss: • $212 • Daily close below invalidates bullish setup 🎯 Targets: • Target 1: $245 • Target 2: $255 • Extension: $270 Bearish / Risk Scenario • Breakdown below $212 → deeper correction • Next support zone: $200 – $195 • Prefer staying sidelined if breakdown occurs Short Fundamental View • AbbVie has a robust pharmaceutical portfolio • Successful transition away from Humira dependency • Strong free cash flow + attractive dividend • Defensive stock with solid long-term outlook • Fundamentally supportive of medium-term bullish continuation
NYSE:ABBVLong
by isahebdadi
ABBV Undervalued Pharma? Strong Dividend Play?ABBV – Financial Performance & SWOT Analysis ABBV Undervalued Pharma? Strong Dividend Play? (1/9) Good evening, folks! ABBV is climbing 🚀, at $ 230.69 up 33.40% YTD per October 10, 2025. Q2 revenue shakes up this pharma play , let’s dive in! 📊🔥 Tag a friend who needs this investing hack! (2/9) – PRICE PERFORMANCE • Last week: $ 230.69, up from $ 230.19 close 📈 • YTD 2025: up 33.40%, outpacing S&P 500 🔄 • Q2 2025: revenue up 6.6% YoY to $15.423B 🚀 This pharma stock’s volatility, earnings beats pop! 💥 (3/9) – MARKET POSITION • Market Cap: $ 407.527B, sector heavyweight 🏆 • Avg Volume: 5.39M shares, high liquidity 💧 • Trend: 686.8% undervalued per Graham Number 👑 This asset’s dominance, holding tight! 🔒 (4/9) – KEY DEVELOPMENTS • Q2 earnings: revenue $15.423B, +6.6% YoY 💰 • Dividends: yield 2.84%, earnings stability 🏭 • Sentiment: value fit with adjusted intangibles 📈 This pharma move, resilient push! ⚡ (5/9) – RISKS IN FOCUS • Regulations: potential pharma impacts ⚠️ • Competition: rising from peers 🆚 • Volatility: beta 0.51 swings 📉 This ticker’s exposure, watch these twists! ⚠️🔄 (6/9) – SWOT: STRENGTHS • Dividend power (strong yield.): stable returns 🌟 • Earnings stability (consistent.): value driver 🤖 • Pharma resilience (sector edge.): growth boost 👥 This asset’s edge, built tough! 💪 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: high P/B ~30, intangibles adjust ⚖️ • Opportunities: Graham undervaluation, sector rebound 🌍 Can this ticker beat the odds? 🎲 Reply with your take! (8/9) – POLL TIME! ABBV’s $ 230.69 value, your vibe? • Bullish: $250+ soon, earnings growth 📈🚀 • Neutral: Steady, risks balanced ⚖️🛡️ • Bearish: $210 looms, regulation hits 📉⚠️ Chime in below! 💬 Tag a friend for this poll! (9/9) – FINAL TAKEAWAY ABBV’s $ 230.69 climb shows resilience 💪, dividends fuel it ⚡. Competition bites 🦈, yet dips are DCA gold 💎. We grab ‘em low, climb like pros! Gem or bust? not advice, just our spin! #ABBV #Investing #Markets #Trading #Finance #ETF #Commodities #DCA #Trends ABBV is undervalued as of October 10, 2025, at $ 230.69, up 33.40% YTD per Yahoo Finance. Q2 revenue shapes its path in the pharma space. Here’s a factual financial and strategic breakdown. **Financial Performance** Price Movement: YTD at $ 230.69, up 33.40%. Broader period shows rebound from lows, outpacing S&P. Q2 adds upside, with revenue $15.423B up 6.6% YoY. Volume & Market Cap: Avg volume 5.39M shares. Market cap at $ 407.527B. Key Metric: Trailing P/E 109.85, forward P/E 16.84. **SWOT Analysis** Strengths: - Strong dividends and earnings stability. - Resilient pharma sector position. - Value fit with adjusted intangibles. Weaknesses: - High P/B ~30 before adjustments. - Potential regulation impacts. - Volatility exposure. Opportunities: - Graham Number undervaluation at 686.8%. - Revenue growth in key segments. - Sector recovery amid stability. Threats: - Competition in pharma. - Market corrections. - Economic factors on healthcare. **ABBV vs. SPY: Key Comparisons** | Aspect | ABBV | SPY | |--------|------|-----| | Purpose & Scope | Pharma and biotech focus | Broad market index tracking | | Dynamics | Beta 0.51 volatility vs. lower 1.00 | Steady benchmark | | Market Position | Up 33.40% YTD, undervalued P/E vs. S&P gains | Stable exposure | **Outlook & Risks** ABBV’s $ 230.69 position shows value edge, with revenue growth. Regulations loom, yet dip grabs turn volatility into gains. Growth or dividends could sway it, but time’s our edge. Gem or fade? Depends on pharma resilience.
NYSE:ABBV
by DCAlpha
2